| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/1000-1/5000 | Human,Mouse,Rat |
| Aliases | APP1; SAMP; XPNPEP; XPNPEPL; XPNPEPL1 |
| WB Predicted band size | 70 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse |
| Immunogen | Synthetic peptide of human XPNPEP1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于XPNPEP1抗体的参考文献示例(注：以下内容为模拟结构，建议通过学术数据库核实真实文献)：
---
1. **文献名称**：*XPNPEP1 Expression in Renal Tubular Cells: Role in Drug Metabolism*
**作者**：Smith J, et al.
**摘要**：本研究通过Western blot和免疫组化技术，使用XPNPEP1特异性抗体分析其在肾脏近端小管细胞中的表达。结果证实XPNPEP1参与局部药物代谢，并揭示了其与肾毒素清除的关联。
2. **文献名称**：*Immunolocalization of XPNPEP1 in Cardiovascular Tissues*
**作者**：Chen L, et al.
**摘要**：利用XPNPEP1抗体对心脏和血管组织进行免疫染色，发现该酶在内皮细胞中高表达，提示其可能通过降解缓激肽调节血压及炎症反应。
3. **文献名称**：*XPNPEP1 Deficiency and Congenital Nephrotic Syndrome*
**作者**：Garcia-Ruiz A, et al.
**摘要**：通过检测XPNPEP1突变患者的肾脏活检样本，发现抗体标记的蛋白表达显著降低，表明其缺失可能导致肾小球滤过屏障功能障碍，与遗传性肾病相关。
4. **文献名称**：*Enzymatic Activity Assay of XPNPEP1 Using Antibody-Based Inhibition*
**作者**：Wang H, et al.
**摘要**：研究开发了一种基于XPNPEP1抗体的酶活性抑制实验，证实该抗体可特异性阻断氨肽酶P的活性，为靶向治疗炎症性疾病提供了实验依据。
---
建议通过PubMed、Google Scholar等平台，以关键词“XPNPEP1 antibody”、“XPNPEP1 immunohistochemistry”或“XPNPEP1 enzyme activity”检索最新文献以获取准确信息。
The XPNPEP1 antibody is a tool used to detect and study X-prolyl aminopeptidase 1 (XPNPEP1), a metallopeptidase involved in cleaving N-terminal amino acids adjacent to proline residues in peptides. XPNPEP1. also known as aminopeptidase P1. plays a role in regulating bioactive peptides, including bradykinin, collagen metabolites, and certain cytokines, influencing processes like inflammation, blood pressure regulation, and tissue remodeling. It is expressed in various tissues, notably the kidneys, liver, and intestines, and functions both intracellularly and on cell membranes.
Research on XPNPEP1 has linked it to diseases such as kidney disorders, hypertension, and inflammatory conditions. For instance, reduced XPNPEP1 activity is associated with impaired bradykinin metabolism, contributing to angioedema. Antibodies against XPNPEP1 are essential for investigating its expression, localization, and function in pathological contexts. They are employed in techniques like Western blotting, immunohistochemistry, and ELISA to quantify protein levels, assess tissue distribution, or explore molecular mechanisms in disease models.
Commercial XPNPEP1 antibodies are typically raised in rabbits or mice using recombinant protein fragments or synthetic peptides as immunogens. Validation includes specificity checks via knockout controls or siRNA knockdown. These reagents aid in advancing studies on peptidase biology, drug development targeting metabolic pathways, and understanding genetic variants linked to disease susceptibility.
×
